HK1024002A1 - Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms - Google Patents

Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms

Info

Publication number
HK1024002A1
HK1024002A1 HK00103287A HK00103287A HK1024002A1 HK 1024002 A1 HK1024002 A1 HK 1024002A1 HK 00103287 A HK00103287 A HK 00103287A HK 00103287 A HK00103287 A HK 00103287A HK 1024002 A1 HK1024002 A1 HK 1024002A1
Authority
HK
Hong Kong
Prior art keywords
crystallisation
crystalline forms
resulting crystalline
tetrahydropyridin
derivative
Prior art date
Application number
HK00103287A
Other languages
English (en)
Inventor
Antoine Caron
Bruno Franc
Olivier Monnier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HK1024002A1 publication Critical patent/HK1024002A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK00103287A 1996-12-23 2000-06-01 Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms HK1024002A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
PCT/FR1997/002393 WO1998028271A1 (fr) 1996-12-23 1997-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (1)

Publication Number Publication Date
HK1024002A1 true HK1024002A1 (en) 2000-09-29

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103287A HK1024002A1 (en) 1996-12-23 2000-06-01 Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms

Country Status (39)

Country Link
EP (1) EP0950050B1 (no)
JP (2) JP4499188B2 (no)
KR (1) KR100586670B1 (no)
CN (1) CN1129580C (no)
AR (1) AR009672A1 (no)
AT (1) ATE307802T1 (no)
AU (1) AU736697B2 (no)
BR (1) BR9714081A (no)
CA (1) CA2275596C (no)
CO (1) CO5070688A1 (no)
CZ (1) CZ296689B6 (no)
DE (1) DE69734460T2 (no)
DK (1) DK0950050T3 (no)
DZ (1) DZ2383A1 (no)
EE (1) EE04188B1 (no)
EG (1) EG21567A (no)
ES (1) ES2251038T3 (no)
FR (1) FR2757543B1 (no)
HK (1) HK1024002A1 (no)
HR (1) HRP970699B1 (no)
HU (1) HU227425B1 (no)
IL (1) IL129938A (no)
IN (1) IN186976B (no)
IS (1) IS2357B (no)
MY (1) MY118015A (no)
NO (1) NO312364B1 (no)
NZ (1) NZ336130A (no)
PL (1) PL190494B1 (no)
RS (1) RS49882B (no)
RU (1) RU2192416C2 (no)
SA (1) SA98180971B1 (no)
SI (1) SI0950050T1 (no)
SK (1) SK285088B6 (no)
TR (1) TR199901363T2 (no)
TW (1) TW518322B (no)
UA (1) UA60324C2 (no)
UY (1) UY24825A1 (no)
WO (1) WO1998028271A1 (no)
ZA (1) ZA9711576B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111857A1 (ja) 2010-03-12 2011-09-15 株式会社日本触媒 吸水性樹脂の製造方法
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
HUP0001387A3 (en) 2002-03-28
CZ296689B6 (cs) 2006-05-17
KR100586670B1 (ko) 2006-06-07
CN1129580C (zh) 2003-12-03
DK0950050T3 (da) 2006-01-23
JP2001507012A (ja) 2001-05-29
RS49882B (sr) 2008-08-07
ZA9711576B (en) 1998-06-25
JP2009197022A (ja) 2009-09-03
EE9900264A (et) 2000-02-15
ES2251038T3 (es) 2006-04-16
YU28999A (sh) 2003-01-31
AR009672A1 (es) 2000-04-26
UA60324C2 (uk) 2003-10-15
DZ2383A1 (fr) 2002-12-28
HUP0001387A2 (hu) 2000-09-28
CA2275596C (en) 2005-10-11
DE69734460D1 (de) 2005-12-01
EE04188B1 (et) 2003-12-15
SK82899A3 (en) 1999-12-10
IS2357B (is) 2008-04-15
PL190494B1 (pl) 2005-12-30
HRP970699B1 (en) 2007-03-31
NO312364B1 (no) 2002-04-29
HU227425B1 (en) 2011-05-30
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
MY118015A (en) 2004-08-30
IN186976B (no) 2001-12-22
NO993076D0 (no) 1999-06-22
SA98180971B1 (ar) 2006-09-13
HRP970699A2 (en) 1998-10-31
EP0950050B1 (fr) 2005-10-26
CO5070688A1 (es) 2001-08-28
CZ229299A3 (cs) 1999-09-15
FR2757543A1 (fr) 1998-06-26
SK285088B6 (sk) 2006-06-01
AU5668498A (en) 1998-07-17
DE69734460T2 (de) 2006-07-06
KR20000069504A (ko) 2000-11-25
BR9714081A (pt) 2000-05-09
IS5076A (is) 1999-06-10
IL129938A (en) 2004-06-20
EP0950050A1 (fr) 1999-10-20
IL129938A0 (en) 2000-02-29
PL334256A1 (en) 2000-02-14
NO993076L (no) 1999-06-22
TW518322B (en) 2003-01-21
TR199901363T2 (xx) 1999-08-23
NZ336130A (en) 2001-01-26
UY24825A1 (es) 1998-04-21
RU2192416C2 (ru) 2002-11-10
CA2275596A1 (en) 1998-07-02
WO1998028271A1 (fr) 1998-07-02
SI0950050T1 (sl) 2006-04-30
JP4499188B2 (ja) 2010-07-07
AU736697B2 (en) 2001-08-02
CN1241180A (zh) 2000-01-12
EG21567A (en) 2001-12-31

Similar Documents

Publication Publication Date Title
HK1023125A1 (en) Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide
PL322501A1 (en) Method of obtaining 2-methyl-thiene-bezodiazepin and crystalline forms thereof
HUP9903454A3 (en) A crystalline form of cefditoren pivoxyl and process for the production of the same
HUP9601857A3 (en) N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them
EP0944626A4 (en) TROPANE DERIVATIVES AND SYNTHESIS METHOD
HUP9603377A3 (en) Crystalline maltitol composition and method for preparing the same
HUP9700536A2 (en) Crystalline vitamin d derivative
HUT74163A (en) New crystalline cepheme-acid-addicional salts and process for producing them
HK1000886A1 (en) A method for production of 3-formyl-tetrahydrofuran
HK1024002A1 (en) Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
AU2567897A (en) Method and means for the production of a spring insert
AU5655698A (en) Suspension crystallization method
AU2274797A (en) Crystalline protease and method for producing same
HK1035530A1 (en) Novel crystal of depsipeptide derivative and a method for producing the same
IL130205A0 (en) Method for producing 1-phenyl-uracil derivatives
AU5655798A (en) Suspension crystallization method
GB9700086D0 (en) Method for producing ceramic superconductor single crystals
GB2319772B (en) 2-phenylazulene derivatives and a manufacturing method of these compounds
GB9621935D0 (en) Method for the control of crystallization
PL318306A1 (en) Method of obtaining crystalline cephuroxime ester
HUP9702472A3 (en) Process for producing allyl-amine derivative and salts thereof
PL325602A1 (en) Alternative crystalline form of thazophenelone
IL125283A0 (en) Process for the preparation of solvated crystalline forms of benzothiophene derivatives
HU9302156D0 (en) Method for producing 11beta-hydroxi-pregnane derivatives
SG33467A1 (en) A bislactone compound and a process for producing the same

Legal Events

Date Code Title Description
PF Patent in force
CHRG Changes in the register
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111223